title: Emerging therapies for the treatment of wet age-related macular degeneration--VEGF Trap-Eye.
abstract: Age-related macular degeneration (AMD) is the leading cause of blindness in the industrialized world. The most severe form of this disease is exudative AMD. It accounts for 10% of cases of AMD and is responsible for approximately 90% cases of severe vision loss due to AMD. Anti-vascular endothelial growth factor (VEGF) therapy changed the standard-of-care for this blinding disease. This article presents one promising new drug for the treatment of exudative AMD--VEGF Trap-Eye.
authors.affiliation: Department of Ophthalmology, Medical University of Lublin, Lublin, Poland. rrejdak@yahoo.com
authors.forename: Robert
authors.initials: R
authors.lastname: Rejdak
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Szkaradek
authors.forename: Paweł
authors.initials: P
authors.lastname: Grieb
authors.forename: Anselm G M
authors.initials: AG
authors.lastname: Jünemann
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000069579:Ranibizumab; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab